Background: The advent of COVID-19 vaccinations saw a rise in myopericarditis cases among young adults all over the United States, especially among males. As of June 11, 2021, 21.5 million second doses of COVID-19 vaccines have been administered in the age group 12 to 29, with 455 reported cases of myocarditis. Purpose: This report outlines a case of myopericarditis diagnosed in the first female young adult in the state of Mississippi after administering the second dose of the Pfizer- BioNTech BNT162b2 mRNA COVID-19 vaccine. The purpose of this case report is to discuss the presentation of myocarditis in a female patient, and the implications of vaccine use in the future. Conclusion: Myocarditis was found to be a rare occurrence among those vaccinated (risk of 0.0021%) compared to those who contract the COVID-19 infection (risk of 0.098%). ACIP recommends COVID-19 vaccinations to be administered in all age groups given the high risk-benefit ratio. In the meantime, CDC continues to investigate myocarditis cases post COVID-19 vaccinations and have found majority of these individuals to have recovered completely. However, the long-term effects of myopericarditis post vaccinations have yet to be determined.
Nair, Vipina MD; Byers, Paul MD; and Taylor, Kathryn G. MD
"Case Report of Myopericarditis post COVID-19 Vaccinations in the first female young adult in MS,"
Journal of Public Health in the Deep South: Vol. 3:
1, Article 5.
Available at: https://scholarsjunction.msstate.edu/jphds/vol3/iss1/5